Format

Send to

Choose Destination
Haematologica. 2019 Jan;104(1):70-81. doi: 10.3324/haematol.2018.195321. Epub 2018 Aug 31.

Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression.

Author information

1
Univ. Bordeaux, Inserm, UMR1034, Biology of Cardiovascular Diseases, Pessac.
2
Univ. Paris Diderot, Inserm, UMRS1148, LVTS, Paris.
3
Inserm U1176, Hemostasis Inflammation Thrombosis, Le Kremlin-Bicêtre.
4
Univ. Paris XI, Inserm U1170, Gustave Roussy Institute, Villejuif.
5
CHU de Bordeaux, Service des Maladies Cardiaques et Vasculaires, Pessac.
6
Univ. Bordeaux, Inserm, UMR1034, Biology of Cardiovascular Diseases, Pessac chloe.james@inserm.fr.
7
CHU de Bordeaux, Laboratoire d'Hématologie, Pessac, France.

Abstract

Thrombosis is the main cause of morbidity and mortality in patients with JAK2V617F myeloproliferative neoplasms. Recent studies have reported the presence of JAK2V617F in endothelial cells of some patients with myeloproliferative neoplasms. We investigated the role of endothelial cells that express JAK2V617F in thrombus formation using an in vitro model of human endothelial cells overexpressing JAK2V617F and an in vivo model of mice with endothelial-specific JAK2V617F expression. Interestingly, these mice displayed a higher propensity for thrombus. When deciphering the mechanisms by which JAK2V617F-expressing endothelial cells promote thrombosis, we observed that they have a pro-adhesive phenotype associated with increased endothelial P-selectin exposure, secondary to degranulation of Weibel-Palade bodies. We demonstrated that P-selectin blockade was sufficient to reduce the increased propensity of thrombosis. Moreover, treatment with hydroxyurea also reduced thrombosis and decreased the pathological interaction between leukocytes and JAK2V617F-expressing endothelial cells through direct reduction of endothelial P-selectin expression. Taken together, our data provide evidence that JAK2V617F-expressing endothelial cells promote thrombosis through induction of endothelial P-selectin expression, which can be reversed by hydroxyurea. Our findings increase our understanding of thrombosis in patients with myeloproliferative neoplasms, at least those with JAK2V617F-positive endothelial cells, and highlight a new role for hydroxyurea. This novel finding provides the proof of concept that an acquired genetic mutation can affect the pro-thrombotic nature of endothelial cells, suggesting that other mutations in endothelial cells could be causal in thrombotic disorders of unknown cause, which account for 50% of recurrent venous thromboses.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center